(Q40497400)

21 September 2017

Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer (English)

1 reference

21 September 2017

1 reference

1 reference

Vijaykumar R Holla

1

1 reference

21 September 2017

Dingzhi Wang

2

1 reference

21 September 2017

Joanne R Brown

3

1 reference

21 September 2017

Jason R Mann

4

1 reference

21 September 2017

Sharada Katkuri

5

1 reference

21 September 2017

Raymond N DuBois

6

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Journal of Biological Chemistry

21 September 2017

1 reference

21 September 2017

280

1 reference

21 September 2017

476-483

1 reference

21 September 2017

1

1 reference

Tumour escape: antitumour effectors too much of a good thing?

21 September 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Regulation of B-cell tolerance and triggering by macrophages and lymphoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Immunology and immunotherapy of human cancer: present concepts and clinical developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

The host-tumor immune conflict: from immunosuppression to resistance and destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Complement resistance of tumor cells: basal and induced mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

The regulation of the complement system: insights from genetically-engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Complement: structure, functions, evolution, and viral molecular mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Decay-accelerating factor: biochemistry, molecular biology, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Expression of complement regulating factors in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

CD55 is over-expressed in the tumour environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

CD55/decay accelerating factor is part of the lipopolysaccharide-induced receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Prostaglandins as modulators of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Effect of nonsteroidal antiinflammatory drugs on immune function

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Prostanoid receptors: subtypes and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Cyclooxygenase 2: a molecular target for cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Cyclooxygenase-2 and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Prostaglandin E2 Suppresses NK Activity In Vivo and Promotes Postoperative Tumor Metastasis in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Anaphylatoxins and infectious and non-infectious inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

C1-inhibitor: an anti-inflammatory reagent with therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Enhanced glomerular prostaglandin formation in experimental membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Targeting complement in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

Shedding light on immunotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M407403200

21 January 2018

Identifiers

DOI

10.1074/JBC.M407403200

1 reference

21 September 2017

1 reference